INTRODUCTION
Tuberculosis (TB) is the leading cause of death by an infectious agent, resulting in 2 million deaths per year. The TB epidemic has worsened over the past 10 years as a consequence of emerging multi-drug resistant TB and extensively drug-resistant TB combined with the significant number of immunocompromised AIDS patients displaying increased susceptibility to TB infection and spread. 1 The current TB vaccine, Bacillus Calmette-Guerin (BCG), is inefficient in protecting against pulmonary TB in adults. Moreover, the protective efficacy of BCG is variable in different clinical trials and populations, suggesting the need for more effective vaccines. 2, 3 As more than one-third of the world's population is infected with Mycobacterium tuberculosis, post-exposure vaccines would additionally be of significant benefit in preventing reactivation of the organism in infected individuals. Therefore, it is important to identify and characterize prophylactic and therapeutic vaccine antigens conferring protection for both noninfected and infected populations.
Significant efforts to identify protective TB antigens have been made to prevent and reduce the spread of infectious disease. Selection of appropriate protective antigens is one of the most essential steps for the development of an effective subunit vaccine. Theoretically, around 4000 M. tuberculosis antigens are documented. The majority of TB antigens have been tested or screened in various prophylactic settings, whereas a relatively small number have been studied in therapeutic models. [4] [5] [6] Ag85A, 7 PstS3, 8 MPT64, 9 ACR, 10, 11 Mtb39, 12 Mtb72F (a fusion protein of Mtb32 and Mtb39) 13 and TB10.4 (ref. 14) were examined in this study. These antigens are recognized immunologically by the majority of M. tuberculosis-infected humans, have shown antigenic potential and provided protection in prophylactic animal TB models. However, only Ag85A, PstS3 and MPT64 have been tested in therapeutic models. We previously demonstrated that Ag85A and PstS3 DNA vaccinations completely block TB reactivation, and significantly prevent secondary infection when combined with chemotherapy. 15 In contrast, reduction of bacterial loads by MPT64 DNA vaccination was not significant compared with that in control mice. 16 As there are no general criteria for defining protective antigens from different vaccination protocols, a comparative study between TB antigens and M. tuberculosis exposure models under a single experimental condition is essential.
DNA vaccines can evoke T cell as well as humoral responses, and thus provide an effective means to induce protective immunity against intracellular pathogens. 17 DNA vaccines are also known for their relative safety and convenience over other delivery methods to evaluate antigen potency. However, weak immunogenicity is an intrinsic limitation of this method. Delivery of molecular adjuvants, cytokines or costimulatory molecules in conjunction with specific antigen-encoded plasmids or fusion of the adjuvant to antigen has been analyzed in an attempt to enhance antigen-specific T-cell immunity by DNA vaccination. 17 Flt3-L has been shown to activate dendritic cells and target antigens to dendritic cells. 18 Moreover, fusion of Flt3-L provides better protection against M. tuberculosis than DNA encoding the single component. 19 In this investigation, we have explored the immunogenicities and protective efficacies of seven TB DNA vaccines against M. tuberculosis in pre-and post-exposure mouse models. Our data show for the first time that the F-Mtb32 DNA vaccine confers the most efficient and broad-spectrum protective immunity in both the exposure models of M. tuberculosis.
RESULTS
We constructed three different Ag85A DNA vaccines, designated Flt3-LAg85A (F-Ag85A), Ag85A-CD40L and Flagellin-Ag85A DNA, with a view to enhance the antigenic potency of TB DNA vaccines. The resulting constructs were compared in terms of their relative ability to induce Ag85A-specific T-cell immune responses in both the spleen and lungs ( Supplementary Figure 1) . At 4 weeks after the last immunization, F-Ag85A DNA elicited the highest antigen-specific interferon-g (IFN-g) responses in mice compared with CD40L-and Flagellin-Ag85A DNA vaccines. Therefore, we constructed additional DNA vaccines expressing the other six TB antigens fused to Flt3-L and evaluated their protective efficacies in two different mouse models of TB. First, the immunogenicities of the seven TB DNA vaccines were evaluated in a prophylactic model. In control groups, empty DNA (pGX10) and BCG were used for vaccination ( Figure 1a ). Antigenspecific IFN-g secretion by the spleen cells was confirmed with the enzyme-linked immunosorbent spot (ELISPOT) assay 4 weeks after the last immunization. In contrast to the control group injected with empty DNA, all groups immunized with DNA vaccines expressing Flt3-L-fused TB antigens showed significant IFN-g production in response to each overlapping peptide pool of TB antigens and CFP. The BCG vaccination induced all the TB antigen-specific T-cell responses tested, comparable to those induced by each TB DNA vaccination (Figure 1b) . Different stimulants were used for each DNA vaccine candidate, and thus direct comparison of the magnitude of T-cell responses between groups was not possible. As fusion of Flt3-L can modulate the characteristics of cellular immune responses, 18, 20 characterization of the source of IFN-g-secreting cells was also performed via intracellular IFN-g staining using the same peptide pools in the lungs and spleen (Table 1) . Interestingly, F-Ag85A and FMtb39 DNA vaccinations mostly induced IFN-g-secreting CD4 cells, while CD8 cells were the major source of IFN-g with the other five DNA vaccines. Mice that received empty DNA showed no antigenspecific responses against neither of the seven peptide pools (data not shown). These data indicate that all DNA vaccines expressing Flt-3L-fused TB antigens efficiently induce strong antigen-specific T-cell responses that are predominately mediated by either CD4 or CD8 cells.
TB antigens
To determine whether the immune responses evoked by each DNA vaccine lead to protection against TB, immunized mice were challenged aerogenically with M. tuberculosis at 4 weeks after the last immunization (Figures 1c and d) . F-Ag85A, F-Mtb39 and F-Mtb32 DNA-vaccinated mice exhibited significantly lower colony-forming unit (CFU) in the lungs than those vaccinated with the other four candidate antigens (Po0.01). Notably, only the F-Mtb32 DNA vaccination generated significant protection in the spleen (Po0.01). Moreover, the F-TB10.4 DNA vaccine elicited a lower number of CFU in spleen than F-Mtb32 DNA on average, although the data did not reach statistical significance. Consistent with these results, BCG prime-DNA boost experiment showed that F-Mtb32 DNA conferred better protective immunity than F-Ag85A in the spleen. F-Ag85A, F-Mtb32 and F-Mtb39 DNA vaccine regimens induced CD4 or CD8 T-cell responses and protection to a greater degree than control empty DNA in the lungs in a boosting experiment using mice previously immunized with BCG (Po0.001; Supplementary  Figure 2 and Supplementary Table 1) . These results collectively indicate that F-Mtb32 DNA generates a stronger prophylactic effect against M. tuberculosis than the other six candidates in a prophylactic infection model. We have previously demonstrated the therapeutic and synergistic effects of Ag85A and PstS3 DNA vaccines during 12 weeks of chemotherapy on reactivation and reinfection of M. tuberculosis. 15 Accordingly, we investigated the immunogenicities and relative protective effects of seven TB DNA vaccines in a modified Cornell model, as described previously. 21 However, in this setting, the drug treatment period for bacterial clearance was shortened from 12 weeks to 6 weeks, compared to the previous study, as we previously found that there was no viable bacterium after 12 weeks of drug treatment, hence, it was not possible to compare the therapeutic effect of DNA vaccines. Following the start of drug treatment, DNA vaccinations were administered five times with 2-week intervals (Figure 2a) . Antigen-specific IFN-g secretion by splenocytes, assayed with ELISPOT at 52 weeks after the last immunization (64 weeks after the primary infection), revealed significantly higher levels of IFN-gsecreting cells from vaccinated mice compared with those from control mice, following stimulation with the respective peptide pools (Figure 2b) . Thus, it appears that DNA vaccine-induced immune responses are effectively sustained for 52 weeks in M. tuberculosisexposed mice. To assess the therapeutic effect of TB DNA vaccines on reactivation, bacterial numbers from therapeutically vaccinated mice were determined at 14, 32 and 64 weeks after aerosol infection. No viable bacillus was detected in the lungs or spleen of mice receiving chemotherapy at 14-32 weeks, regardless of TB DNA vaccination (data not shown), consistent with previous results. 22 At week 64, 71% (5/7) of buffer control mice contained reactivated bacilli in the lung or spleen (Figure 2c ). On the other hand, M. tuberculosis was recovered from only 14% (1/7) of mice vaccinated with F-Ag85A, F-PstS3, FMtb32 or F-TB10.4 DNA (Po0.05, compared with the control group, w 2 -tests). Moreover, F-Ag85A and F-Mtb32 DNA vaccinations reduced the M. tuberculosis bacterial burden in the lungs to undetectable level, and one mouse from each group showed reactivation in spleen.
DISCUSSION
The protective efficacy of TB antigens has been studied by several investigators, and is difficult to compare due to the diversity of murine models of M. tuberculosis. For instance, one study showed that the early secreted antigen, ESAT-6, affords protection, as evident from the significant reduction in the bacterial number in the lungs, while other groups reported minimal protective activity with no statistical significance in mice. 23, 24 In therapeutic settings, HSP65 and Ag85A are the most extensively tested antigens, but their protective efficacies remain a subject of controversy. 21, 22, 25 Head-to-head comparison of potent TB antigens under a single experimental condition may be the ideal approach for identifying protective antigens, especially when infection models are diverse like TB. 26 In this study, we initially demonstrated that F-Mtb32 DNA vaccination provides superior protective immunity than the other six candidates, either as a prophylactic or therapeutic vaccine against M. tuberculosis. The prophylactic effect of Mtb32 is consistent with the previous results obtained using the Mtb72f fusion protein (Mtb32(C-terminal)-Mtb39-Mtb32 (N-terminal)) in a mouse challenge model. 13, 27 In contrast, we observed no therapeutic effect with Abbreviation: IFN-g, interferon-g. a Mice were immunized with the DNA vaccine candidates as described in Figure 1 . Four weeks after the last boost immunization, the lungs and spleens of vaccinated mice (n¼4) were pooled and stimulated in vitro with indicated peptide pools. b Lung and spleen cells were gated on the lymphocyte population based on size, and the percentage of CD4 + and CD8 + cells producing IFN-g was obtained by flow cytometric analysis. c Mice immunized with empty DNA showed undetectable level (o0.1%) against all stimulant described above (data not shown).
the F-Mtb39 DNA vaccination. Mtb32 is a putative serine protease found in the culture filtrate of M. tuberculosis. 4, 28 We generated a point mutation at the trypsin active-site triad (His, Asp and Ser to Ala) in view of the report that vaccination of HIV-1 protease DNA following inactivation of the enzyme via point mutation enhances proteasespecific antibody and T-cell immune responses. 29 Additionally, the inactivated HIV-1 protease acts as a strong T-cell adjuvant for genetic vaccines exerting an antitumor effect in a HPV cancer mouse model. 30 It is suggested that antigens expressed during the first phase of growth initially provide protection against M. tuberculosis infection, whereas those expressed during the late stages help to prevent reactivation of the disease. 4 The protective effects of early secreted culture filtrate proteins, including ESAT-6, TB10.4, Ag85A and Ag85B, are well established. Rv2660c, a latency-associated protein, has recently been identified as an effective post-exposure vaccine. 31 Nevertheless, the high abundance of antigen is not always correlated with the level protective efficacy. For example, while the expression of ESAT-6 is ten times higher than that of Ag85 complexes in the lungs of mouse, studies have shown that the bacterial burdens in the lungs are similarly reduced between mice immunized with ESAT-6 and Ag85B. It was previously showed that a single MHC II-peptide complex on the surface of an antigen-presenting cell is sufficient for activating cognate CD4 T cells, indicating that small amount of antigen is able to evoke potent responses. 32 Based on these results, we postulate that Mtb32 antigen related to protection is expressed during both early and late stages of infection. MPT64 and ACR did not protect mice in both the experiment models from M. tuberculosis challenge in our study. Other groups have shown that the therapeutic effect of MPT64 in mice is not significant, whereas the prophylactic effect is controversial. In a low-dose aerosol challenge model, MPT64 DNA immunization protected mice by about 0.38 log 10 CFU in the lungs with statistical significance. 33 In another model using the M. tuberculosis Erdman strain, the relative protection level induced by MPT64 DNA vaccination was 0.5 (relative to the BCG-vaccinated group, taken as 1), which was closer to that of vector-injected mice. 34 Previous reports showed no protection by ACR, one of the earliest dormancy-related antigens identified. 34 We concluded that this antigen, evaluated as a F-ACR DNA vaccine, has no immunotherapeutic benefits in mice, indicating that dormancy-related antigens do not necessarily prevent reactivation of latent disease.
PstS3 suppressed reactivation but did not reduce the bacterial burden in a prophylactic setting in our murine models. The immunotherapeutic effect of PstS3 is consistent with the previous reports. 15 In contrast, another group showed that PstS3 DNA vaccination reduced CFU from 8 to 12 weeks after infection. 8 This discrepancy may be attributed to varying experimental conditions, such as challenge route (intravenous vs aerosol), antigen engineering (PstS3 vs F-PstS3) and protocols. Mice immunized with F-TB10.4 DNA among the seven candidate antigens were examined and had second lowest number of CFUs in spleen, but only partial protection was evident due to high variations, in keeping with a previous report showing that vaccination with recombinant TB10.4 protein protected mice against infection by 0.4 log 10 . 24 The therapeutic effect of TB10.4 was initially evaluated in this study. As reported previously, the increasing cytotoxic potential of TB10.4-specific CD8 + T cells during later stages of infection supports the utility of the TB10.4 antigen as a potential target during this time period. 35 Our data collectively show that a DNA vaccine encoding F-Mtb32 induces sustained protective immune responses in pre-and post-exposure mouse models of pulmonary TB. Based on these promising findings, further studies focusing on the evaluation and characterization of F-Mtb32 as a universal TB vaccine targeting both primary and latent TB infection are warranted.
MATERIALS AND METHODS Mice
Specific pathogen-free 6-to 8-week-old female C57BL/6 mice were purchased from Charles River Breeding Laboratories (Shizuoka, Japan), maintained under barrier conditions in a BL-3 biohazard animal room at Yonsei University Medical Research Center, and fed a sterile commercial mouse diet and water ad libitum.
Plasmid DNA construction
To improve in vivo pDNA performance in mammalian cells, codon-optimized Ag85A, PstS3, Mpt64, ACR, Mtb39, Mtb32, TB10.4 and Flt3-L genes were synthesized on the basis of the codon usage for mammalian cell expression by GeneScript (http://www.genscript.com) and inserted in the pGX10 vector. 21 The signal sequence of tissue plasminogen activator (tPA) was fused to the 5¢ of Ag85A. Flt3-L were isolated and cloned into pGX10/tPA-Ag85A to generate pGX10/tPA-Flt3-L-Ag85A (pGX10/F-Ag85A). Ag85A gene was replaced with the other six genes to generate pGX10/F-PstS3, pGX10/F-Mpt64, pGX10/ F-ACR, pGX10/F-Mtb39, pGX10/F-Mtb32 and pGX10/F-TB10.4. To verify expression of proteins, the HA-epitope was fused to the 3¢ of each fusion genes.
Primary infection model
Mice were immunized three times intramuscularly with 50 mg of DNA per mouse (one quadriceps muscle) at 4-week intervals as indicated. Electroporation for DNA vaccination was performed with a field strength of 100 V cm À1 (constant), six pulses for 20 ms, each using an ECM 830 electroporator (BTX, San Diego, CA, USA). As a positive control, single dose of 10 6 CFU of BCG was subcutaneously vaccinated at 4 weeks after the first DNA vaccination. Four weeks after the last immunization, mice were exposed to a predetermined dose of M. tuberculosis H37Rv for 60 min in the inhalation chamber of an airborne infection apparatus (Glas-Col, Terre Haute, IN, USA). Bacteria were counted 1 day after exposure, and B200 viable M. tuberculosis were found to have been delivered to the lungs. Protection was monitored at 4 weeks post infection from the lungs and spleen, as previously described. 21 
Therapeutic model
The modified Cornell model by Ha et al. 21 was employed with minor modification. Briefly, mice were treated with INH and PZA at 25 mg kg À1 per day and 1000 mg kg À1 per day, respectively, by diet for 6 weeks, starting 4 weeks after aerosol infection. During chemotherapy, mice were immunized with 50 mg of DNA vaccine five times at 2-week intervals as described above in primary infection model or injection of buffer instead of DNA vaccine. After the completion of DNA immunization, mice received intraperitoneal injections with 200 ml of dexamethasone (Sigma, St Louis, MO, USA) at 6 mg kg À1 of body weight in every 2 days for 2 weeks (from 24 to 26 weeks, from 40 to 42 weeks and from 54 to 56 weeks post infection) to induce bacteria reactivation. Reactivation was monitored at 14 and 64 weeks after infection from the lungs and spleen.
Cell isolation and peptides
Spleen and lung cells were obtained as previously described. 21 Briefly, lungs were perfused with PBS via the right ventricle, cut into small pieces, and digested with 0.7 mg ml À1 collagenase type I (Sigma-Aldrich, St Louis, MO, USA) and 30 mg ml À1 DNase I (Sigma-Aldrich) for 45 min at 37 1C. Lung fragments were then crushed through a 70-mm Flacon strainer using pipettes, washed and enumerated. Cells were stimulated with CFP (10 mg ml À1 ) 21 or a peptide pool in RPMI-1640 supplemented with 10% heat inactivated fetal bovine serum, 2-mercaptoethanol, and penicillin and streptomycin. Synthetic 10-mer overlapping peptides were designed using the peptide-generator tool at the Los Alamos National Laboratory (http://www.hiv.lanl.gov/content/ sequence/PEPTGEN/peptgen.html). A total of 28, 33, 23, 15, 54, 33 and 11 peptides spanning mature forms of Ag85A, PstS3, Mpt64, ACR, Mtb32, Mtb39 and TB10.4 of M. tuberculosis, respectively, were synthesized by PEPTRON (http://www.peptron.com) or GeneScript (http://www.genscript.com).
IFN-c ELISPOT assay
IFN-g ELISPOT assays were performed as previously described, except for the use of the Ag85A, PstS3, Mpt64, ACR, Mtb39, Mtb32 and TB10.4 peptide pool (1 mg ml À1 for each peptide) or CFP (10 mg ml À1 ) instead of the E2 peptide in the stimulation step. 36 
Flow cytometry
To determine the number of M. tuberculosis-specific IFN-g-producing cells by intracellular cytokine staining, cells from the lungs and spleen were stimulated with the indicated peptide pool (1 mg ml À1 for each peptide) for 10 h at 37 1C. Brefeldin A (eBioscience, San Diego, CA, USA) was added and cells were incubated for an additional 5 h before staining. The cells were stained for CD4 or CD8 surface markers (eBioscience), washed, and permeabilized with the Cytofix/Cytoperm kit, followed by intracellular cytokine staining for IFN-g (eBioscience). Flow cytometry was performed on a FACS Calibur (BD Biosciences, San Jose, CA, USA). The data were analyzed using CellQuest Pro (BD Biosciences) and FACSDiva (BD Biosciences).
Statistical analysis
To analyze the differences in CFU numbers between groups, the Wilcoxon Mann-Whitney test was performed using SPSS Version 10.0 (SPSS Inc., Chicago, IL, USA) in prophylactic model. P-value of o0.01 was considered significant. In therapeutic model, statistical significance between the treatment groups was calculated using the w 2 -test. P-value of o0.05 was considered significant.
